No revenue or earnings surprise to trade on. The stock will move on the NXP900 Phase 1b data readout expected in summer 2026. Monitor for patient enrollment updates and any early efficacy signals from the ongoing monotherapy and combination arms.
Price Chart
Executive Summary
Nuvectis Pharma reported Q1 2026 financial results, highlighting continued enrollment in the NXP900 Phase 1b program and preclinical data presented at AACR. The net loss widened to $6.1M from $5.3M in the prior year quarter, with cash burn reducing the cash position to $25.1M. Management expects a preliminary Phase 1b data readout in summer 2026.
Key Financial Metrics
Key Facts
- Net loss of $6.1M for Q1 2026 vs $5.3M in Q1 2025
- Cash and cash equivalents of $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025
- R&D expenses of $4.1M vs $3.7M YoY, driven by manufacturing and clinical trial costs
- Management expects preliminary NXP900 Phase 1b data readout in summer 2026
- Preclinical data at AACR supported NXP900 combination with sotorasib in NSCLC models
Financial Impact
Net loss increased $0.8M YoY; cash burn of $6.5M in Q1 2026
Risk Factors
- Clinical trial failure or disappointing Phase 1b data
- Cash runway only into H2 2027, requiring future capital raises
- No approved products or revenue stream
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-055264 |
| Document: tm2613389d1_8k.htm | 0001104659-26-055264 |
| Document: 0001104659-26-055264-index-headers.html | 0001104659-26-055264 |
| Document: 0001104659-26-055264-index.html | 0001104659-26-055264 |
| Document: 0001104659-26-055264.txt | 0001104659-26-055264 |
| 8-K Data (Synthetic) | 0001104659-26-055264 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $20.10 $23.06 | ▲ +14.73% | ▲ +15.96% | $18.49 (−8.01%) |
Jul 1, 2026 16w ago | Insider Cluster | $19.52 $20.69 | ▲ +5.99% | ▲ +8.18% | $18.49 (−5.28%) |
Jun 30, 2026 16w ago | 8-K | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.49 (+5.28%) |
Jun 30, 2026 16w ago | 424B5 | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.49 (+5.28%) |
Jun 29, 2026 17w ago | Press Release | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.49 (−0.54%) |
Jun 29, 2026 17w ago | 424B5 | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.49 (−0.54%) |
Jun 29, 2026 17w ago | 8-K | $18.39 $19.54 | ▲ +6.25% | ▲ +7.28% | $18.49 (+0.54%) |
May 5, 2026 24w ago | 8-K | $9.71 $9.51 | ▼ −2.06% | ▼ −7.01% | $18.49 (+90.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers